Press Releases

Occlutech Appoints Thomas J. Bogenschütz as Chairman of the Board

July 9, 2025

Occlutech® Announces Commercial Cases of Occlutech ASD Occluder Device Implantation in the U.S.

August 28, 2024

Occlutech® Announces FDA Approval of its Occlutech® ASD Occluder and Occlutech® Pistol Pusher, a Minimally Invasive Cardiac Device and Delivery System to Treat Atrial Septal Defects

January 8, 2024

Occlutech Year-end report 2022 – Significant uptick in sales growth as transformation processes are reaching an end

May 3, 2023

Occlutech receives subscription commitment of bonds amounting to EUR 40 million in nominal value under a total frame of EUR 75 million to finance US expansion and growth

April 5, 2023

Occlutech announces first patient enrollment in important US pivotal study for the Atrial Flow Regulator (FROST-HF)

March 13, 2023

Occlutech announces change to the Executive Management Team

February 1, 2023

Occlutech continues its progress in US FDA study OCCLUFLEX – enrolls first patient in Europe

January 31, 2023

Occlutech announces new member to the Executive Management Team by appointing Chief Medical Officer

November 1, 2022

Occlutech announces new members to the Executive Management Team – appoints Chief Commercial Officer and Vice President Global Business Development & Marketing

September 6, 2022

Load More Press Releases

Subscribe